9 May 2019

To: Recipients of M100, 29th ed.

From: Jennifer K. Adams, MT(ASCP), MSHA
Vice President, Standards and Quality

Subject: Correction

This notice is intended to inform users of a correction made to CLSI document M100, *Performance Standards for Antimicrobial Susceptibility Testing*, 29th ed. The correction is described below and shown as highlighted text in the table excerpt.

**Table 2C. Zone Diameter and MIC Breakpoints for *Staphylococcus* spp.:**

In the Testing Conditions box, in the “Medium” section, the special media conditions for testing daptomycin were omitted. The text has been corrected to include “CAMHB supplemented to 50 µg/mL calcium for daptomycin.”

**Table 2C. Zone Diameter and MIC Breakpoints for *Staphylococcus* spp.**

<table>
<thead>
<tr>
<th>Testing Conditions</th>
</tr>
</thead>
</table>
| **Medium:** Disk diffusion: MHA  
Broth dilution: CAMHB; CAMHB + 2% NaCl for oxacillin; CAMHB supplemented to 50 µg/mL calcium for daptomycin  
Agar dilution: MHA; MHA + 2% NaCl for oxacillin.  
**NOTE:** Agar dilution has not been validated for daptomycin. |
| **Inoculum:** Colony suspension, equivalent to a 0.5 McFarland standard |
| **Incubation:** 35 °C ± 2 °C; ambient air  
Disk diffusion: 16–18 hours; 24 hours (for cefoxitin when testing *Staphylococcus* spp., excluding *S. aureus*, *S. lugdunensis*, *S. pseudintermedius*, and *S. schleiferi*);  
Dilution methods: 16–20 hours; 24 hours for oxacillin and vancomycin  
Testing at temperatures above 35 °C may not detect MRS. |

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service ([customerservice@clsi.org](mailto:customerservice@clsi.org)).

We appreciate your commitment to CLSI and regret any inconvenience.